Christopher Daigle, MD
Pulmonary Disease · Nashua, NHNPI 1861503567
Payments from drug & device makers
What this record shows
This record is dominated by education: $10,313 of the $11,810 with a category attached, or 87.3%. Intuitive Surgical accounts for 87.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $8,300 and has fallen 95.9% since, to $344 in 2025. Among pulmonary disease clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $171.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- AstraZeneca$346
- GSK$301
- Inspire Medical Systems, Inc.$182
- Inari Medical, Inc.$179
- Sanofi$94
- plus $349 from 10 others
What the payments were for
- Food & beverage$1,49813%
- Education$10,31387%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $10,358 |
| AstraZeneca | 15 | $346 |
| GSK | 25 | $301 |
| Inspire Medical Systems, Inc. | 3 | $182 |
| Inari Medical, Inc. | 1 | $179 |
| Sanofi | 4 | $94 |
| Harmony Biosciences LLC | 2 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Jazz Pharmaceuticals Inc. | 2 | $51 |
| Pulmonx Corporation | 1 | $45 |
| W. L. Gore & Associates, Inc. | 1 | $37 |
| United Therapeutics Corporation | 2 | $33 |
| Itamar Medical Inc | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Grifols USA, LLC | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$10,250
- FLOWTRIEVER CATHETER, S$179
- CT THROMBECTOMY SYSTEM KIT$179
- Inspire$129
How this compares
$11,810 in reported general payments places this provider in the 90th percentile of 78 pulmonary disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 184 | $144,298 |
| Breo ElliptaFluticasone/Vilanterol | 192 | $93,826 |
| Spiriva RespimatTiotropium Bromide | 80 | $60,546 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $47,406 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 156 | $20,765 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $19,884 |
| SymbicortBudesonide/Formoterol Fumarate | 50 | $17,297 |
| Spiriva HandihalerTiotropium Bromide | 20 | $15,019 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $14,894 |
| EliquisApixaban | 12 | $8,190 |
| Arnuity ElliptaFluticasone Furoate | 30 | $7,842 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 310 | $7,786 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 35 | $7,186 |
| XareltoRivaroxaban | 12 | $6,452 |
| Wixela InhubFluticasone Propion/Salmeterol | 80 | $6,300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $301 | $293,372481 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $346 | $37,18182 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 78 pulmonary disease providers in New Hampshire.
Other pulmonary disease in Nashua
- Naim AounNashua$6K
- Eduardo Velez CalderonNashua$707
- Branko KeslerNashua$616
- Mark PohlmanNashua$321
- Joseph HouNashua$147
- Gregory FanarasNashua$22
- Donald MahlerLebanon$411K
- Bianca MonteiroDover$43K
- Jeffrey StewartLebanon$30K
- Erik SwensonLebanon$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.